ArticleCell biology and toxicology2026
IGF2BP3 promotes glycolysis of osteosarcoma stem cells by reading RNA m⁶A to stabilize ENO1 and promote malignant biological behavior of osteosarcoma.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRIM25 facilitates mitochondrial dysfunction and extracellular matrix degradation by enhancing USP7-driven ENO1 deubiquitination during intervertebral disc degeneration.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma stem cells (OSSCs) play a central role in driving osteosarcoma (OS) progression by promoting migration, proliferation, self-renewal, chemotherapy resistance, and immune evasion. However, the molecular mechanisms that sustain stemness in OS are still not well defined. In this study, we demonstrate that elevated expression of IGF2BP3 in OS correlates with the maintenance of OSSC stemness. Overexpression of IGF2BP3 enhanced OS self-renewal, cisplatin resistance, proliferation, migration, and invasion by increasing glycolysis in OSSCs. Mechanistically, as an m⁶A reader, IGF2BP3 recognized and bound m⁶A-modified ENO1 mRNA, thereby stabilizing its expression. METTL3, the methyltransferase responsible for the m⁶A modification of ENO1, synergized with IGF2BP3 to further elevate ENO1 expression. Upregulation of ENO1 promoted glycolysis and stemness in OSSCs and enhanced OS self-renewal, cisplatin resistance, invasion, migration, and proliferation. Notably, in vivo knockdown of IGF2BP3 and ENO1, together with glycolytic inhibition, attenuated OS stemness and tumorigenicity. Moreover, combined suppression of IGF2BP3 and ENO1 (IGF2BP3⁻/ENO1⁻) or ENO1 knockdown plus oxamate treatment (ENO1⁻/Oxamate) further reduced the tumorigenic potential of these cells. The results clearly demonstrate that the IGF2BP3/ENO1/glycolytic axis reduces tumorigenic potential, therefore the authors logically and convincingly conclude that this axis is a major regulator of OS stemness, chemotherapy resistance, and tumorigenesis, making it a very attractive therapeutic target for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.